ZAI LAB LIMITED Proceeds from Maturities, Prepayments and Calls of Short-term Investments
ZAI LAB LIMITED (ZLAB) reported Proceeds from Maturities, Prepayments and Calls of Short-term Investments of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments · last filed 2026-08-06
- ZAI LAB LIMITED proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2026-06-30 was $0.00.
- ZAI LAB LIMITED proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- ZAI LAB LIMITED proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2025-12-31 was $0.00.
- ZAI LAB LIMITED proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2025-09-30 was $0.00.
- ZAI LAB LIMITED proceeds from maturities, prepayments and calls of short-term investments for fiscal 2025 was $330.00M, a 1924.54% increase from fiscal 2024.
- ZAI LAB LIMITED proceeds from maturities, prepayments and calls of short-term investments for fiscal 2024 was $16.30M, a 86.15% decline from fiscal 2023.
- ZAI LAB LIMITED proceeds from maturities, prepayments and calls of short-term investments for fiscal 2023 was $117.70M, a 83.31% decline from fiscal 2022.
- ZAI LAB LIMITED proceeds from maturities, prepayments and calls of short-term investments for fiscal 2022 was $705.27M, a 5.19% decline from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 3 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 6 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 9 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $330.00M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $330.00M 10-Q · filed 2025-11-06 | $330.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $330.00M 10-Q · filed 2026-08-06 | $330.00M derived: sum of 3 quarters · filed 2026-08-06 | $330.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $330.00M 10-Q · filed 2026-05-07 | $330.00M derived: sum of 2 quarters · filed 2026-05-07 | $330.00M derived: sum of 3 quarters · filed 2026-05-07 | $330.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $16.30M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $16.30M 10-Q · filed 2025-11-06 | $31.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $16.30M 10-Q · filed 2025-08-07 | $31.60M derived: sum of 3 quarters · filed 2026-02-26 | $49.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $16.30M 10-Q · filed 2025-05-08 | $31.60M derived: sum of 2 quarters · filed 2026-02-26 | $49.50M derived: sum of 3 quarters · filed 2026-02-26 | $84.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $15.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $33.20M derived: sum of 2 quarters · filed 2026-02-26 | $68.25M derived: sum of 3 quarters · filed 2026-02-26 | $117.70M 10-K · filed 2026-02-26 |
| 2023-09-30 | $17.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $52.95M derived: sum of 2 quarters · filed 2024-11-12 | $102.40M 10-Q · filed 2024-11-12 | $102.40M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $35.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $84.50M 10-Q · filed 2024-08-06 | $84.50M derived: sum of 3 quarters · filed 2025-02-27 | $659.77M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $49.45M 10-Q · filed 2024-05-08 | $49.45M derived: sum of 2 quarters · filed 2025-02-27 | $624.72M derived: sum of 3 quarters · filed 2025-02-27 | $654.72M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $575.27M derived: sum of 2 quarters · filed 2025-02-27 | $605.27M derived: sum of 3 quarters · filed 2025-02-27 | $705.27M 10-K · filed 2025-02-27 |
| 2022-09-30 | $575.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $605.27M derived: sum of 2 quarters · filed 2023-11-07 | $705.27M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $30.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $130.00M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $100.00M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $743.90M 10-K · filed 2024-02-27 | |||
| 2020-12-31 | $405.00M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |